<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>) is a <z:e sem="disease" ids="C0009782" disease_type="Disease or Syndrome" abbrv="">connective tissue disorder</z:e> manifested by variable and pleiotropic features in the skeletal, ocular, and cardiovascular systems </plain></SENT>
<SENT sid="1" pm="."><plain>The average life span in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> is about 35 years </plain></SENT>
<SENT sid="2" pm="."><plain>A group with much more severe <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> and a mean life span of approximately 1 year also exists </plain></SENT>
<SENT sid="3" pm="."><plain>We refer to this latter group as "neonatal <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>" (nMFS) </plain></SENT>
<SENT sid="4" pm="."><plain>Fibrillin defects are now known to be the cause of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> and nMFS </plain></SENT>
<SENT sid="5" pm="."><plain>Immunofluorescence studies were the first to demonstrate this association </plain></SENT>
<SENT sid="6" pm="."><plain>Here we describe immunofluorescence studies in a series of 10 neonates and summarize their salient clinical features </plain></SENT>
<SENT sid="7" pm="."><plain>In vitro accumulation of fibrillin reactive fibers was assayed using monoclonal antibodies to fibrillin in hyperconfluent fibroblast cultures </plain></SENT>
<SENT sid="8" pm="."><plain>As was previously observed in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e>, fibroblast cultures from nMFS patients showed an apparent decrease in accumulation of immunostainable fibrillin </plain></SENT>
<SENT sid="9" pm="."><plain>Significantly, however, the <z:mp ids='MP_0000002'>morphology</z:mp> of the immunostained fibrils in the nMFS cultures were abnormal and differed not only from control cultures, but also from those seen in cultures of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> fibroblasts </plain></SENT>
<SENT sid="10" pm="."><plain>The nMFS fibrils appeared short, fragmented, and frayed, characteristics that are not seen in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Both the clinical and fibrillin <z:mp ids='MP_0000002'>morphology</z:mp> data provide evidence to suggest a useful subclassification of nMFS in the spectrum of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MFS</z:e> </plain></SENT>
</text></document>